QC
TEVA icon

Qalhat Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Qalhat Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-114,000
Closed -$920K – 16
2022
Q3 		$920K Hold
114,000
– – 0.28% 14
2022
Q2 		$857K Buy
+114,000
New +$993K 0.31% 12

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Qalhat Capital's TEVA Position: Q4 2022 in Review

Qalhat Capital sold out of Teva Pharmaceuticals (TEVA) in Q4 2022, closing a stake of 114,000 shares — an estimated $920K sold.

Qalhat Capital first reported a position in TEVA in Q2 2022 and held it in 2 quarters. The position peaked at $920K in Q3 2022. 421 funds tracked by Wall St. Rank hold TEVA as of Q4 2022.

  • Qalhat Capital reported no remaining Teva Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Qalhat Capital sold 114,000 Teva Pharmaceuticals shares in Q4 2022, an estimated $920K.
  • Qalhat Capital first reported a position in Teva Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Qalhat Capital's Teva Pharmaceuticals position peaked at $920K in Q3 2022.
  • 421 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2022.

Based on Qalhat Capital's 13F filing for Q4 2022, filed 14 Feb 2023.